The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 April 2026•

1 min read

Pulse Biosciences Enrolls First Patients in Pivotal nPulse Cardiac Catheter Study

Key Facts

1Pulse Biosciences announced the enrollment of the first 7 patients in its NANOPULSE-AF IDE pivotal clinical study.

2The study evaluates nanosecond pulsed field ablation (nsPFA) technology for treating paroxysmal atrial fibrillation.

Version History

1 additional source confirmed this story

Pulse Biosciences (Nasdaq: PLSE) has officially commenced patient enrollment for its NANOPULSE-AF IDE pivotal clinical study. The company announced that the first 7 patients have been enrolled in this prospective, multicenter investigation to evaluate the nPulse Cardiac Catheter System. This proprietary technology utilizes nanosecond pulsed field ablation (nsPFA) specifically designed to treat drug-resistant symptomatic paroxysmal atrial fibrillation. Reaching this clinical milestone is a critical step for the medical technology firm as it seeks regulatory clearance from the FDA. Successful completion of this pivotal trial could significantly enhance the company's market position in the cardiac ablation sector. The study marks the final major clinical hurdle before the company can pursue full commercialization of the system.